• Je něco špatně v tomto záznamu ?

International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators

RB. Price, N. Kissel, A. Baumeister, R. Rohac, ML. Woody, ED. Ballard, CA. Zarate, W. Deakin, CG. Abdallah, A. Feder, DS. Charney, MF. Grunebaum, JJ. Mann, SJ. Mathew, B. Gallagher, DM. McLoughlin, JW. Murrough, S. Muthukumaraswamy, R. McMillan,...

. 2022 ; 27 (12) : 5096-5112. [pub] 20220907

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu metaanalýza, časopisecké články, Research Support, N.I.H., Extramural

Perzistentní odkaz   https://www.medvik.cz/link/bmc22032442

Grantová podpora
K23 MH119225 NIMH NIH HHS - United States
R01 MH113857 NIMH NIH HHS - United States

E-zdroje Online Plný text

NLK ProQuest Central od 2000-01-01 do Před 1 rokem
Open Access Digital Library od 1997-01-01
Health & Medicine (ProQuest) od 2000-01-01 do Před 1 rokem
Psychology Database (ProQuest) od 2000-01-01 do Před 1 rokem

Odkazy

PubMed 36071111
DOI 10.1038/s41380-022-01757-7
Knihovny.cz E-zdroje

Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset antidepressant properties, but little is known regarding which patients are most likely to benefit, limiting personalized prescriptions. We identified randomized controlled trials of IV ketamine that recruited individuals with a relevant psychiatric diagnosis (e.g., unipolar or bipolar depression; post-traumatic stress disorder), included one or more control arms, did not provide any other study-administered treatment in conjunction with ketamine (although clinically prescribed concurrent treatments were allowable), and assessed outcome using either the Montgomery-Åsberg Depression Rating Scale or the Hamilton Rating Scale for Depression (HRSD-17). Individual patient-level data for at least one outcome was obtained from 17 of 25 eligible trials [pooled n = 809]. Rates of participant-level data availability across 33 moderators that were solicited from these 17 studies ranged from 10.8% to 100% (median = 55.6%). After data harmonization, moderators available in at least 40% of the dataset were tested sequentially, as well as with a data-driven, combined moderator approach. Robust main effects of ketamine on acute [~24-hours; β*(95% CI) = 0.58 (0.44, 0.72); p < 0.0001] and post-acute [~7 days; β*(95% CI) = 0.38 (0.23, 0.54); p < 0.0001] depression severity were observed. Two study-level moderators emerged as significant: ketamine effects (relative to placebo) were larger in studies that required a higher degree of previous treatment resistance to federal regulatory agency-approved antidepressant medications (≥2 failed trials) for study entry; and in studies that used a crossover design. A comprehensive data-driven search for combined moderators identified statistically significant, but modest and clinically uninformative, effects (effect size r ≤ 0.29, a small-medium effect). Ketamine robustly reduces depressive symptoms in a heterogeneous range of patients, with benefit relative to placebo even greater in patients more resistant to prior medications. In this largest effort to date to apply precision medicine approaches to ketamine treatment, no clinical or demographic patient-level features were detected that could be used to guide ketamine treatment decisions.Review Registration: PROSPERO Identifier: CRD42021235630.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22032442
003      
CZ-PrNML
005      
20230131151035.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41380-022-01757-7 $2 doi
035    __
$a (PubMed)36071111
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Price, Rebecca B $u University of Pittsburgh, Pittsburgh, PA, USA. rebecca.price@stanfordalumni.org $1 https://orcid.org/0000000275904325
245    10
$a International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators / $c RB. Price, N. Kissel, A. Baumeister, R. Rohac, ML. Woody, ED. Ballard, CA. Zarate, W. Deakin, CG. Abdallah, A. Feder, DS. Charney, MF. Grunebaum, JJ. Mann, SJ. Mathew, B. Gallagher, DM. McLoughlin, JW. Murrough, S. Muthukumaraswamy, R. McMillan, R. Sumner, G. Papakostas, M. Fava, R. Hock, JL. Phillips, P. Blier, P. Shiroma, P. Šóš, TP. Su, MH. Chen, M. Tiger, J. Lundberg, ST. Wilkinson, ML. Wallace
520    9_
$a Depression is disabling and highly prevalent. Intravenous (IV) ketamine displays rapid-onset antidepressant properties, but little is known regarding which patients are most likely to benefit, limiting personalized prescriptions. We identified randomized controlled trials of IV ketamine that recruited individuals with a relevant psychiatric diagnosis (e.g., unipolar or bipolar depression; post-traumatic stress disorder), included one or more control arms, did not provide any other study-administered treatment in conjunction with ketamine (although clinically prescribed concurrent treatments were allowable), and assessed outcome using either the Montgomery-Åsberg Depression Rating Scale or the Hamilton Rating Scale for Depression (HRSD-17). Individual patient-level data for at least one outcome was obtained from 17 of 25 eligible trials [pooled n = 809]. Rates of participant-level data availability across 33 moderators that were solicited from these 17 studies ranged from 10.8% to 100% (median = 55.6%). After data harmonization, moderators available in at least 40% of the dataset were tested sequentially, as well as with a data-driven, combined moderator approach. Robust main effects of ketamine on acute [~24-hours; β*(95% CI) = 0.58 (0.44, 0.72); p < 0.0001] and post-acute [~7 days; β*(95% CI) = 0.38 (0.23, 0.54); p < 0.0001] depression severity were observed. Two study-level moderators emerged as significant: ketamine effects (relative to placebo) were larger in studies that required a higher degree of previous treatment resistance to federal regulatory agency-approved antidepressant medications (≥2 failed trials) for study entry; and in studies that used a crossover design. A comprehensive data-driven search for combined moderators identified statistically significant, but modest and clinically uninformative, effects (effect size r ≤ 0.29, a small-medium effect). Ketamine robustly reduces depressive symptoms in a heterogeneous range of patients, with benefit relative to placebo even greater in patients more resistant to prior medications. In this largest effort to date to apply precision medicine approaches to ketamine treatment, no clinical or demographic patient-level features were detected that could be used to guide ketamine treatment decisions.Review Registration: PROSPERO Identifier: CRD42021235630.
650    _2
$a lidé $7 D006801
650    12
$a ketamin $x terapeutické užití $7 D007649
650    _2
$a deprese $x farmakoterapie $7 D003863
650    12
$a bipolární porucha $x farmakoterapie $7 D001714
650    _2
$a antidepresiva $x terapeutické užití $7 D000928
650    _2
$a intravenózní podání $7 D061605
650    _2
$a výsledek terapie $7 D016896
655    _2
$a metaanalýza $7 D017418
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
700    1_
$a Kissel, Nicholas $u Carnegie Mellon University, Pittsburgh, PA, USA $1 https://orcid.org/0000000245217903
700    1_
$a Baumeister, Andrew $u University of Pittsburgh, Pittsburgh, PA, USA
700    1_
$a Rohac, Rebecca $u University of Pittsburgh, Pittsburgh, PA, USA
700    1_
$a Woody, Mary L $u University of Pittsburgh, Pittsburgh, PA, USA
700    1_
$a Ballard, Elizabeth D $u National Institutes of Health, Bethesda, MD, USA $1 https://orcid.org/0000000153040127
700    1_
$a Zarate, Carlos A $u National Institutes of Health, Bethesda, MD, USA
700    1_
$a Deakin, William $u University of Manchester, Manchester, UK $1 https://orcid.org/000000022750962X
700    1_
$a Abdallah, Chadi G $u Baylor College of Medicine, Houston, TX, USA $u Michael E. Debakey VA Medical Center, Houston, TX, USA $1 https://orcid.org/0000000157836181
700    1_
$a Feder, Adriana $u Icahn School of Medicine at Mount Sinai, New York, NY, USA $1 https://orcid.org/000000032931310X
700    1_
$a Charney, Dennis S $u Icahn School of Medicine at Mount Sinai, New York, NY, USA
700    1_
$a Grunebaum, Michael F $u Columbia University, New York, NY, USA $1 https://orcid.org/0000000159403478
700    1_
$a Mann, J John $u Columbia University, New York, NY, USA
700    1_
$a Mathew, Sanjay J $u Baylor College of Medicine, Houston, TX, USA $u Michael E. Debakey VA Medical Center, Houston, TX, USA $1 https://orcid.org/0000000227156641
700    1_
$a Gallagher, Bronagh $u Trinity College Dublin, Dublin, Ireland
700    1_
$a McLoughlin, Declan M $u Trinity College Dublin, Dublin, Ireland $1 https://orcid.org/0000000345742799
700    1_
$a Murrough, James W $u Icahn School of Medicine at Mount Sinai, New York, NY, USA $1 https://orcid.org/0000000162861242
700    1_
$a Muthukumaraswamy, Suresh $u University of Auckland, Auckland, New Zealand $1 https://orcid.org/0000000170423920
700    1_
$a McMillan, Rebecca $u University of Auckland, Auckland, New Zealand
700    1_
$a Sumner, Rachael $u University of Auckland, Auckland, New Zealand $1 https://orcid.org/0000000226524617
700    1_
$a Papakostas, George $u Harvard Medical School, Boston, MA, USA
700    1_
$a Fava, Maurizio $u Harvard Medical School, Boston, MA, USA
700    1_
$a Hock, Rebecca $u Harvard Medical School, Boston, MA, USA
700    1_
$a Phillips, Jennifer L $u University of Ottawa, Ottawa, ON, Canada $1 https://orcid.org/0000000196358602
700    1_
$a Blier, Pierre $u University of Ottawa, Ottawa, ON, Canada
700    1_
$a Shiroma, Paulo $u Minneapolis VA Medical Center, Minneapolis, MN, USA
700    1_
$a Šóš, Peter $u Psychiatrie Slaný s.r.o., Slaný, Czech Republic
700    1_
$a Su, Tung-Ping $u National Yang-Ming University, Taipei, Taiwan
700    1_
$a Chen, Mu-Hong $u National Yang-Ming University, Taipei, Taiwan $1 https://orcid.org/0000000165161073
700    1_
$a Tiger, Mikael $u Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000184958125
700    1_
$a Lundberg, Johan $u Karolinska Institutet, Stockholm, Sweden $1 https://orcid.org/0000000242983936
700    1_
$a Wilkinson, Samuel T $u Yale School of Medicine, New Haven, CT, USA
700    1_
$a Wallace, Meredith L $u University of Pittsburgh, Pittsburgh, PA, USA
773    0_
$w MED00008047 $t Molecular psychiatry $x 1476-5578 $g Roč. 27, č. 12 (2022), s. 5096-5112
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36071111 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131151031 $b ABA008
999    __
$a ok $b bmc $g 1891290 $s 1183777
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 27 $c 12 $d 5096-5112 $e 20220907 $i 1476-5578 $m Molecular psychiatry $n Mol Psychiatry $x MED00008047
GRA    __
$a K23 MH119225 $p NIMH NIH HHS $2 United States
GRA    __
$a R01 MH113857 $p NIMH NIH HHS $2 United States
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace